Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2024 - 2025)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Asset Writedowns and Impairment came in at -$649000.0 in Q4 2025, up 98.87% year-on-year from -$326342.8 in Q4 2024, and down 549.0% quarter-over-quarter from -$100000.0 in Q3 2025.
Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Tonix Pharmaceuticals Holding's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at -$649000.0 for Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 98.87% year-over-year to -$649000.0 in Q4 2025; TTM through Dec 2025 was -$57.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $669000.0, down 55.1% from the prior year.
- Asset Writedowns and Impairment eased to -$649000.0 in Q4 2025 per TNXP's latest filing, from -$100000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $59.0 million in Q2 2024 and bottomed at -$57.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - |
| 10 | Tonix Pharmaceuticals Holding | 138.65 Mn | 138.65 Mn | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -649,000.00 |
| Dec 31, 2025 | -649,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Dec 31, 2024 | -57.47 Mn |
| Dec 31, 2024 | -57.47 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 58.96 Mn |
| Jun 30, 2024 | 58.96 Mn |